[1] J D WINKLER B W K Thermos. Differential effects of fluphenazine-N-mustard, on calmodulin activity and on D1 and D2 dopaminergic responses.[J]. Psychopharmacology, 1987, 92 3: 285-291. DOI:
10.1007/bf00210832[2] W N HAIT. Pharmacological properties of fluphenazine-mustard, an irreversible calmodulin antagonist.[J]. Molecular Pharmacology, 1987, 32 3: 404-409.
[3] Z H QIN. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.[J]. Molecular Pharmacology, 1995, 48 4: 730-737.
[4] K. THERMOS B. W J D Winkler. Comparison of the effects of fluphenazine-n-mustard on dopamine binding sites and on behavior induced by apomorphine in supersensitive mice[J]. Neuropharmacology, 1987, 26 10: Pages 1473-1480. DOI:
10.1016/0028-3908(87)90166-3[5] G DAVIDKOVA. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.[J]. Journal of Pharmacology and Experimental Therapeutics, 1998, 285 3: 1187-1196.
[6] MI-KYUNG HWANG Seong H K Yong Ki Min. Calmodulin inhibition contributes to sensitize TRAIL-induced apoptosis in human lung cancer H1299 cells.[J]. Biochemistry and Cell Biology, 2009: 919-926. DOI:
10.1139/o09-058